Abstract
Targeted cellular immunotherapy with bifunctional antibodies (bsAbs) has emerged as a promising therapeutic approach for cancer over the last two decades. Progress in antibody engineering has led to the generation of many different types of antibody-derived entities that display at least two binding specificities. Most bsAbs consist of large IgG-like proteins with multiple antigen-binding regions containing Fc parts or smaller entities without Fc. BsAbs have the potential to engage effector cells of the immune system, thereby overcoming some of the immune response escape mechanisms of tumor cells. Preclinical and clinical trials of various bsAb constructs have demonstrated impressive results in terms of immune effector cell retargeting and induction of efficient anti-tumor responses. This review provides an overview of the established bsAbs focusing on improvements in format and design as well as the mechanisms of action of the most promising candidates and describes the results of the most recent clinical studies.
Keywords: Bispecific antibody, antibody engineering, cancer, immunotherapy, clinical trials, T cells, NK cells, cell death.
Current Pharmaceutical Biotechnology
Title:Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Volume: 16 Issue: 8
Author(s): Cindy Grandjenette, Mario Dicato and Marc Diederich
Affiliation:
Keywords: Bispecific antibody, antibody engineering, cancer, immunotherapy, clinical trials, T cells, NK cells, cell death.
Abstract: Targeted cellular immunotherapy with bifunctional antibodies (bsAbs) has emerged as a promising therapeutic approach for cancer over the last two decades. Progress in antibody engineering has led to the generation of many different types of antibody-derived entities that display at least two binding specificities. Most bsAbs consist of large IgG-like proteins with multiple antigen-binding regions containing Fc parts or smaller entities without Fc. BsAbs have the potential to engage effector cells of the immune system, thereby overcoming some of the immune response escape mechanisms of tumor cells. Preclinical and clinical trials of various bsAb constructs have demonstrated impressive results in terms of immune effector cell retargeting and induction of efficient anti-tumor responses. This review provides an overview of the established bsAbs focusing on improvements in format and design as well as the mechanisms of action of the most promising candidates and describes the results of the most recent clinical studies.
Export Options
About this article
Cite this article as:
Grandjenette Cindy, Dicato Mario and Diederich Marc, Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells, Current Pharmaceutical Biotechnology 2015; 16 (8) . https://dx.doi.org/10.2174/1389201016666150505124037
DOI https://dx.doi.org/10.2174/1389201016666150505124037 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Strategies Combining Biomaterials and Stem Cells for Bone, Liver and Skin Regeneration
Current Stem Cell Research & Therapy Traditional Chinese Medicine Remedy to Jury: The Pharmacological Basis for the Use of Shikonin as an Anticancer Therapy
Current Medicinal Chemistry Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Editorial [ The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello ]
Current Cancer Therapy Reviews Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Impact of MCP -1 in Atherosclerosis
Current Pharmaceutical Design Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Structure Prediction of Neuroendocrine Convertase -2: A Potential Target in Various Cancers
Protein & Peptide Letters ROCK Inhibitor Y-27632 Promotes Human Retinal Pigment Epithelium Survival by Altering Cellular Biomechanical Properties
Current Molecular Medicine Meet Our Editorial Board Member
Current Signal Transduction Therapy Meet Our Editorial Board Member
Current Pharmacogenomics and Personalized Medicine Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Enhanced Pro-Apoptotic Effect of Tetrandrine Loaded Nanoparticles Against Osteosarcoma Cells
Current Drug Delivery Atypical PKCι as Target for Glioblastoma Therapy
Current Cancer Drug Targets Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy
Current Medicinal Chemistry Targeting Apoptotic Signaling Pathways in Human Lung Cancer
Current Cancer Drug Targets Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Meet Our Editorial Board Member
Current Bioinformatics